Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
Strong EPS estimate revisions powered gains across Healthcare, Technology, and Communication Services stocks between June 22-28. QNRX led with a 44.9% jump after a 9.5pp revision to 54.8% EPS growth, while NMAX's 217.8pp revision to 376.9% drove a 25.1% rally. BILL added a CRO appointment to sustain its 21.3% gain.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| QNRX | Healthcare | 2026-06-23 | +9.5pp | +44.9% |
| NTSK | Technology | 2026-06-22 | N/A | +30.3% |
| NMAX | Communication Services | 2026-06-28 | +217.8pp | +25.1% |
| MRNA | Healthcare | 2026-06-22 | N/A | +22.2% |
| BILL | Technology | 2026-06-22 | N/A | +21.3% |
Why did QNRX stock jump in July 2026?
QNRX jumped 44.9% (from $3.25 to $4.71) after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23.
The revision in the healthcare sector signaled improved profitability expectations, driving buying interest despite no specific company news. The screener detected the revision early, and the stock has continued to climb over the following week.
QNRX EPS revision history → · Screener snapshot from 2026-06-23 →
FAQ: QNRX
Why did QNRX stock jump in June 2026?
QNRX jumped 44.9% after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23.
What is QNRX's EPS growth estimate?
QNRX's forward EPS growth estimate was revised to 54.8% as of June 23.
Is QNRX a buy after the rally?
The 54.8% EPS growth estimate suggests strong earnings acceleration, but investors should evaluate the company's fundamentals and sector conditions before buying.
Why did NTSK stock jump in July 2026?
NTSK jumped 30.3% (from $8.95 to $11.66) after analysts raised its forward EPS growth estimate to 112.0% on June 22.
The technology sector saw renewed optimism, and the triple-digit growth estimate attracted momentum investors. The stock rallied steadily without additional earnings-related news catalysts.
NTSK EPS revision history → · Screener snapshot from 2026-06-22 →
FAQ: NTSK
Why did NTSK stock surge?
NTSK surged 30.3% after analysts raised its forward EPS growth estimate to 112.0% on June 22.
What is NTSK's EPS growth estimate?
NTSK's forward EPS growth estimate is 112.0%, indicating high expected earnings growth.
What caused NTSK's rally?
The triple-digit EPS growth estimate revision on June 22 triggered buying interest, and the stock continued to rally without additional news.
Why did NMAX stock jump in July 2026?
NMAX jumped 25.1% (from $7.49 to $9.37) after analysts raised its forward EPS growth estimate from 159.1% to 376.9% on June 28.
This massive 217.8 percentage point revision reflects a dramatically improved earnings outlook for the communication services company. The market quickly priced in the upgrade, pushing shares higher over the following three days.
NMAX EPS revision history → · Screener snapshot from 2026-06-28 →
FAQ: NMAX
Why did NMAX stock jump?
NMAX jumped 25.1% after analysts raised its forward EPS growth estimate from 159.1% to 376.9% on June 28.
What is NMAX's EPS growth estimate?
NMAX's forward EPS growth estimate was revised to 376.9%, a massive increase of 217.8 percentage points.
Is NMAX a buy after the rally?
The exceptionally high EPS growth estimate could attract growth investors, but the stock's volatility warrants caution.
Why did MRNA stock jump in July 2026?
MRNA jumped 22.2% (from $59.35 to $72.50) after analysts raised its forward EPS growth estimate to 45.1% on June 22.
The healthcare biotech stock benefited from the upward revision amid positive sector momentum. No specific news accompanied the move, but the EPS estimate revision acted as a catalyst for the rally.
MRNA EPS revision history → · Screener snapshot from 2026-06-22 →
FAQ: MRNA
Why did MRNA stock jump in June 2026?
MRNA jumped 22.2% after analysts raised its forward EPS growth estimate to 45.1% on June 22.
What is MRNA's EPS growth estimate?
MRNA's forward EPS growth estimate is 45.1% as of the June 22 revision.
What caused MRNA's surge?
The EPS estimate revision in the healthcare sector acted as a catalyst, with no specific news from the company.
Why did BILL stock jump in July 2026?
BILL jumped 21.3% (from $31.96 to $38.78) after analysts raised its forward EPS growth estimate to 26.3% on June 22.
The technology stock gained further momentum when BILL named Jonathan Leaf as Chief Revenue Officer on June 25, reinforcing confidence in the growth trajectory. The combination of the EPS revision and the executive hire drove the sustained rally.
BILL EPS revision history → · Screener snapshot from 2026-06-22 →
FAQ: BILL
Why did BILL stock jump?
BILL jumped 21.3% after analysts raised its forward EPS growth estimate to 26.3% on June 22, aided by a CRO appointment on June 25.
What is BILL's EPS growth estimate?
BILL's forward EPS growth estimate is 26.3% as of the June 22 revision.
What caused BILL's surge?
The EPS revision and the naming of Jonathan Leaf as Chief Revenue Officer on June 25 reinforced confidence in BILL's growth trajectory.
Today's top movers demonstrate that EPS estimate revisions remain a powerful leading indicator for price action, particularly when revisions are large or accompanied by reinforcing news. The mix of healthcare, technology, and communication services winners suggests broad-based optimism in growth estimates.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →